Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4014586 | 0.98 | KMT2A (0.63) | KMT2AHTTMEN1LMNARAB9A | |
| Hydrochloric Acid SCHEMBL4012346 | 0.98 | KMT2A (0.63) | KMT2AHTTMEN1LMNARAB9A | |
| SCHEMBL13235126 | 0.84 | HTT (0.81) | KMT2AHTTMEN1LMNARAB9A | |
| SCHEMBL18317944 | 0.84 | KMT2A (0.50) | KMT2AHTTMEN1LMNARAB9A | |
| SCHEMBL29519193 | 0.83 | SMN1; SMN2 (0.54) | KMT2AHTTMEN1LMNARAB9A | |
| SCHEMBL1226530 | 0.83 | SMN1; SMN2 (0.54) | KMT2AHTTMEN1LMNARAB9A | |
| SCHEMBL2097424 | 0.82 | KMT2A (0.60) | KMT2AHTTMEN1LMNARAB9A | |
| SCHEMBL2050021 | 0.82 | L3MBTL1 (0.67) | KMT2AHTTMEN1LMNARAB9A | |
| SCHEMBL27622875 | 0.81 | HDAC1 (0.65) | KMT2AHTTMEN1LMNARAB9A | |
| SCHEMBL14157620 | 0.81 | LMNA (0.46) | KMT2AHTTMEN1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024259241-A1 | 5-HT2A RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Transneural Therapeutics, Inc. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| EP-4146644-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-2021226003-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3029026-B1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG A ST CO LTD (KR) | 2018-12-05 | — | — | EP | disclosed |
| US-9828339-B2 | Biphenyl derivatives and methods for preparing same | DONG-A ST CO., LTD (KR) | 2017-11-28 | — | — | US | disclosed |
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | DONG-A ST CO., LTD (KR) | 2016-06-23 | — | — | US | disclosed |
| EP-3029026-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | Dong-A ST Co., Ltd. (KR) | 2016-06-08 | — | — | EP | disclosed |
| EP-3029026-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | Dong-A ST Co., Ltd. (KR) | 2016-06-08 | — | — | EP | disclosed |
| US-9272990-B2 | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis | AMIRA PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2008041095-A1 | SULFONAMIDE DERIVATIVES AS ADRENERGIC AGONISTS AND MUSCARINIC ANTAGONISTS | PFIZER LIMITED (GB) | 2008-04-10 | — | — | WO | disclosed |
| CN-1970544-A | Benzimidazole-like heterocyclic compound and its intermediate synthesis method | SHANGHAI INST ORGANIC CHEM (CN) | 2007-05-30 | — | — | CN | disclosed |
| EP-1765339-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-03-28 | — | — | EP | disclosed |
| EP-1711183-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-10-18 | — | — | EP | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006005057-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005067537-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-0276051-B1 | ANTINEOPLASTIC COMPOUNDS | ARIZONA BOARD OF REGENTS (US) | 1991-08-21 | — | — | EP | disclosed |
| EP-0391473-A1 | Process for producing carbamates | ENICHEM SYNTHESIS S.p.A. (IT) | 1990-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176816-A1 | NOVEL BIPHENYL DERIVATIVE AND METHOD FOR PREPARING SAME | CHRM2, CHRM3, CHRM5 | KMT2A 3945/4885HTT 1566/4885MEN1 2329/4885 |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | KMT2A 3013/4885HTT 4501/4885MEN1 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.